Citius Oncology Q3 FY2026: $7.1M Revenue, 44 Institutions Ordering LYMPHIR
CTOR sits 80% above its 52-week low of $0.491 on elevated volume (2.8× avg).
Summary
Citius Oncology reported Q3 FY2026 revenue of $1.5M and nine-month revenue of $7.1M, driven by growing institutional demand for LYMPHIR. The company posted a net loss of $8.9M for the quarter and $41.1M for the nine months, with $16.6M in cash on hand.
Key Events · Earnings and Guidance · CTOR
-
Q3 Revenue Reaches $1.5M
Q3 FY2026 revenue came in at $1.5M, up from zero in the prior-year quarter, driven by LYMPHIR sales. Nine-month revenue totaled $7.1M.
-
Institutional Demand Accelerates
Since launch, 44 institutions have prescribed and ordered LYMPHIR. Vial orders grew 31% sequentially to 926 in Q3, with 383 vials ordered in July 2026—the largest month to date.
-
Net Loss Widens to $8.9M
The company posted a net loss of $8.9M for Q3 FY2026, compared to $5.4M in the prior-year quarter. Nine-month net loss was $41.1M, including a $19.7M CMO contract cancellation charge.
-
Cash Position at $16.6M
Cash and cash equivalents totaled $16.6M as of June 30, 2026, after receiving $9.7M from warrant exercises and funding $10.0M under a senior secured term loan facility.
Analysis · CTOR · Life Sciences
LYMPHIR's commercial traction is accelerating, with Q3 FY2026 revenue reaching $1.5M and nine-month revenue totaling $7.1M. Institutional demand is building—44 institutions have now ordered the drug, and vial orders rose 31% sequentially. Yet the company continues to burn cash, posting a net loss of $8.9M for the quarter and $41.1M for the nine-month period. The balance sheet shows $16.6M in cash, which management believes is sufficient to fund operations for at least the next 12 months, but a going concern warning and Nasdaq delisting risk remain. The expansion of the commercial team to 29 field-based professionals signals a commitment to accelerating the launch, though the path to profitability remains uncertain.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 36.6% of the 951 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTOR was trading at $0.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.6M. The 52-week trading range was $0.49 to $2.25. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.